Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Rising incidence of pancreatic & biliary cancers

Gallbladder cancer prevalence has climbed to 20.3% among at-risk groups, notably individuals with gallstones, creating a large pool of patients who require endoscopic intervention.^{[1]Ali Afzal, “Epidemiology of gall bladder cancer and its prevalence worldwide: a meta-analysis,” Orphanet Journal of Rare Diseases, ojrd.biomedcentral.com} Early-onset pancreatic cancer cases add clinical complexity, demanding specialised diagnostic and therapeutic protocols tailored to younger populations. These epidemiological shifts lift procedure volumes beyond normal demographic growth, especially in high-income nations with established reimbursement systems. Post-ERCP pancreatitis affects up to 15% of patients and adds more than USD 200 million in annual U.S. costs, intensifying the search for safer technologies.^{[2]Patrick Smith, “Preventing Pancreatitis After ERCP,” Johns Hopkins Medicine, hopkinsmedicine.org}Ageing societies and lifestyle risk factors combine to keep long-term demand for ERCP solutions strong.

Growing preference for single-use duodenoscopes to curb cross-infection

Hospitals increasingly choose single-use duodenoscopes, driven by safety, operational efficiency, and new reimbursement pathways. Boston Scientific’s EXALT Model D shows performance parity with reusable devices across seven peer-reviewed studies while removing cross-infection risks. The U.S. Centers for Medicare & Medicaid Services has granted an add-on payment for Ambu’s aScope Duodeno, alleviating cost concerns for administrators. These policy incentives, coupled with lower legal liability, accelerate broader adoption beyond high-risk cases.

AI-enabled imaging & navigation boosts cannulation success

Artificial-intelligence software raises selective cannulation success and diagnostic accuracy. Meta-analysis data reveal 93% sensitivity and 90% specificity for pancreatic cancer detection with AI-enhanced EUS, achieving an area under the curve of 0.95.^{[3]Hua Yin, “The Value of Artificial Intelligence Techniques in Predicting Pancreatic Ductal Adenocarcinoma with EUS Images,” Endoscopic Ultrasound, journals.lww.com} Deep-learning models show 97% accuracy in spotting bile-duct dilatation on MRCP scans. Olympus plans to commercialise an AI endoscopy ecosystem in 2025, embedding cloud-based analytics to support real-time decision-making.

Reimbursement expansion for outpatient ERCP in OECD markets

Thirty new U.S. gastrointestinal endoscopy centres opened in 2023, mirroring expanded insurer coverage that equalises payment for outpatient and inpatient ERCP procedures. Ambulatory settings lower hospital infection risks, shorten recovery, and improve patient satisfaction while cutting facility costs. These benefits align with payer shifts to value-based purchasing, spurring health systems to invest in ambulatory ERCP capability.

High capital & per-procedure cost of disposable scopes

Although infection risk falls to near zero, single-use devices still cost more per case than reusables, straining budgets in systems with tight reimbursement. Hospitals saved USD 451 million through device reprocessing programs in 2024, illustrating pressure to contain spending. As economies of scale improve and payment models evolve, the cost differential is expected to narrow.

Shortage of ERCP-skilled endoscopists in emerging markets

Advanced ERCP requires extensive training. Olympus has partnered with Rizal Medical Center in the Philippines to build a regional training hub, yet the pipeline cannot meet rising demand quickly. Until more clinicians acquire these skills, procedure volumes may lag equipment availability.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Segment Analysis

Duodenoscopes held 46.98% of Endoscopic Retrograde Cholangiopancreatography market share in 2025 and remain on track to grow at an 11.62% CAGR through 2031. Hospital infection-control policies and supportive reimbursement drive brisk conversion to single-use models, while hybrid scopes with disposable tips help institutions with tight budgets transition gradually. Olympus, Boston Scientific, and Ambu compete closely, each offering ergonomics, imaging clarity, and sterile packaging that answer clinician demands. As institutions retire ageing reusable fleets, procurement cycles increasingly favour newer single-use or hybrid options that lower reprocessing load and litigation exposure.

Endotherapy devices form the second-largest revenue block and cover sphincterotomes, guidewires, lithotripters, and stents. Growing case complexity, particularly in pancreatic interventions, sustains multi-device demand per procedure. Radiofrequency ablation catheters such as Habib EndoHPB broaden therapeutic scope and extend stent patency. Accessories and consumables enjoy steady volume growth, reflecting the overall expansion of procedures rather than large price swings.

Biliary sphincterotomy accounted for 26.35% of Endoscopic Retrograde Cholangiopancreatography market size in 2025, confirming its role as the traditional workhorse procedure. Pancreatic duct stenting, however, posts the quickest rise at a 12.25% CAGR as clinicians manage pancreatitis complications and malignant strictures with endoscopic techniques that once required surgery. Advances in imaging and wire technology improve cannulation precision, allowing safe navigation of complex duct anatomy. As procedural confidence grows, hospitals adopt expanded indications, driving a mix shift toward higher-value pancreatic work.

Pancreatic duct dilatation and combined EUS-ERCP techniques continue to gain ground. Technical success rates up to 92% in EUS-guided drainage highlight the expanding therapeutic envelope. Device firms market mini-sphincterotomes for difficult cannulations, reinforcing procedure adoption in less experienced hands. This broadening toolkit accelerates the transition from purely diagnostic ERCP toward comprehensive endoscopic therapy.

Hospitals captured 58.81% revenue share in 2025 by handling complex cases that demand anaesthesia support, imaging infrastructure, and intensive post-procedure monitoring. Many tertiary centres also act as regional referral hubs, ensuring high patient throughput. Yet ambulatory surgery centres are forecast to record a 10.54% CAGR as payers reward lower facility fees and faster discharge. Purpose-built outpatient suites slash turnover times and free inpatient capacity for more acute care. Health systems respond by spinning up hospital-owned ASCs, blending capital efficiency with clinical oversight.

Specialty and GI clinics fill a complementary role for routine diagnostic ERCP, patient follow-up, and minor therapeutic updates. As device makers refine smaller-footprint imaging systems, these clinics gain increased capability to perform straightforward cases, easing backlog at large hospitals. Collectively, the end-user mix reflects the healthcare sector’s broader shift to decentralised, cost-effective service delivery.

Reusable duodenoscope platforms controlled 68.05% market share in 2025, supported by existing reprocessing suites and sunk capital. Fully single-use systems, however, register an 11.21% CAGR as infection-control priorities gain urgency. Administrators weigh the financial trade-off between upfront capital avoidance and higher per-case consumable expense. Hybrid approaches—reusable main bodies with disposable tips—provide a stepping-stone for budget-conscious providers who still seek lower contamination risk.

Environmental sustainability also enters procurement criteria. Low-water detergents and energy-efficient washers improve the lifecycle profile of reusable fleets, while manufacturers investigate recyclable polymers for single-use models. These parallel innovations keep all technology categories in active contention, ensuring diverse supplier strategies in the medium term.

Biliary disorders represented 61.02% Endoscopic Retrograde Cholangiopancreatography market share in 2025, anchored in well-defined protocols for stone removal and stricture management. Pancreatic disorders, supported by emerging radiofrequency ablation evidence and EUS-guided access, are set to climb at a 9.28% CAGR. Improved survival rates in pancreatic cancer patients augment follow-on endoscopic needs for stent exchange and drainage procedures. For high-risk surgical candidates, endoscopic therapy provides a less invasive alternative with shorter recovery windows.

This application shift is mirrored in academic training curricula, which now dedicate more rotation time to complex pancreatic interventions. Device suppliers bundle biliary and pancreatic toolkits, simplifying inventory and driving cross-application utilisation. The net effect keeps overall procedure counts rising, and pushes average selling prices upward as advanced disposables replace generic accessories.

Geography Analysis

North America Endoscopic Retrograde Cholangiopancreatography (ERCP) Market

North America maintained 39.12% of Endoscopic Retrograde Cholangiopancreatography market share in 2025 due to robust reimbursement, mature training networks, and early roll-out of single-use scopes. U.S. ambulatory centre growth signals confidence in outpatient ERCP safety profiles, while Canadian provinces adopt similar policies to relieve inpatient pressures. Market players use the region to launch premium technologies, assuming rapid payer uptake and clinician buy-in.

Europe Endoscopic Retrograde Cholangiopancreatography (ERCP) Market

Europe ranks second, driven by stringent infection-control mandates and environmental goals that elevate demand for hybrid and single-use options. The new EU Medical Device Regulation imposes uniform safety standards, smoothing cross-border distribution and encouraging pan-European procurement contracts. Hospitals in Germany and France lead adoption of AI-supported imaging, citing evidence of improved cannulation and reduced fluoroscopy exposure.

APAC Endoscopic Retrograde Cholangiopancreatography (ERCP) Market

Asia-Pacific posts the fastest expansion at 9.92% CAGR. Investments in endoscopy training centres, as seen in the Philippines, bring advanced ERCP to previously under-served populations. China and India stand out with rising pancreatic cancer incidence, translating to higher procedure volumes. Government health-insurance schemes widen access, yet specialist shortages still cap throughput in rural areas. Regional private providers respond by offering executive health packages that include ERCP screening for high-risk demographics.

MEA and South America Endoscopic Retrograde Cholangiopancreatography (ERCP) Market

The Middle East & Africa and South America show smaller absolute numbers but strong relative growth. Sustained oil revenues support capital spending in Gulf Cooperation Council countries, while Brazilian teaching hospitals establish ERCP fellowships to retain talent. These regions rely on simplified scope platforms and tele-mentoring programs to overcome limited local expertise.

Regulatory Landscape

ERCP devices primarily fall under established medical-device pathways. In the United States, the FDA 510(k) route remains central for endoscopes and associated accessories, supported by recent clearances such as Fujifilm Corporation’s Endoscope Model ED-S100TP (K251861, March 2026) and Olympus Medical Systems’ single-use distal cover MAJ-2315 (K253646, February 2026). This clearance cadence supports iterative product updates in duodenoscopes, distal-end components, and ERCP consumables while aligning with Class II expectations for performance, biocompatibility, and labeling in real-world clinical use.

In Europe, EU MDR-related requirements continue to determine market access for endoscopy portfolios, alongside ongoing updates to recognized technical benchmarks. EUDAMED registration became mandatory on 28 May 2026 for MDR/IVDR devices, increasing operational focus on UDI and device-module readiness, and on consistent device nomenclature coding. In 2026, Commission Implementing Decisions (EU) 2026/1231 and 2026/1313 (effective 17 June 2026) updated the harmonized standards list supporting presumption of conformity. ISO activity also progressed in 2026, including publication of ISO 8600-1:2025 (general requirements for medical endoscopes and endotherapy devices), which shapes verification and documentation practices in global submissions.

Value Chain Analysis

The ERCP value chain starts with specialized inputs such as optical assemblies, CMOS sensors, fiber-optics, medical-grade polymers, and precision metals. It then moves into midstream manufacturing and assembly of duodenoscopes (reusable, hybrid, and fully single-use) and endotherapy devices (guidewires, cannulation devices, sphincterotomes, stents, and lithotripters). Quality systems, sterilization validation for reusable components, and packaging and sterility assurance for single-use platforms are key value-add steps that influence both cost and time-to-market, particularly as product designs increasingly integrate imaging enhancements and workflow features geared toward ERCP efficiency.

Downstream, distribution uses direct sales and group purchasing pathways into hospitals, ambulatory surgery centers, and specialty/GI clinics. For reusable fleets, sterile reprocessing services and washer-disinfector ecosystems remain important. Supply reliability is shaped by component lead times and logistics, and a 2025 medical device supply-chain survey identified availability and lead times as a primary operational pain point for many manufacturers. That has reinforced moves toward multi-sourcing and regionalized supply strategies. The shift toward single-use duodenoscopes also changes the channel mix and inventory model by increasing reliance on consumables replenishment and sterile supply-chain performance, rather than only on capital equipment cycles.

Market Opportunities and Future Outlook

Clinical standardization and measurable quality targets create a practical whitespace for manufacturers to align ERCP device design, labeling, and training with defined performance metrics. In February 2026, the American College of Gastroenterology (ACG) and the American Society for Gastrointestinal Endoscopy (ASGE) updated ERCP-specific quality indicators, with 13 measures across preprocedure, intraprocedure, and postprocedure domains. This pushes providers toward tighter tracking of outcomes such as technical success and downstream unplanned utilization. As a result, demand increases for device ecosystems that reduce variability in cannulation and therapy steps, and for accessory portfolios that support consistent execution across mixed-acuity sites, including outpatient settings.

Product innovation and portfolio expansion are also supported by ongoing regulatory throughput and guideline updates. FDA 510(k) clearances for ERCP consumables, including Olympus Medical Systems’ Single Use Cannula V series (K250573, May 2025) and Medi-Globe GmbH’s Endoflux biliary and pancreatic stent sets (K251658, April 2026), show active development and substitution potential in high-volume disposable categories tied to both safety and workflow. In parallel, the World Endoscopy Organization’s June 2025 guideline update on biliary cannulation and sphincterotomy techniques provides a globally referenced practice baseline, which supports broader adoption of standardized techniques and device kits mapped to recommended procedural steps.